LONDON, Dec. 29, 2010 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc (OTCBB:LLTP) is pleased to announce that it has appointed Mary K. Pendergast J.D., LL.M., as its advisor for Regulatory and Strategic Matters.
Mary Pendergast is President of Pendergast Consulting, a legal and regulatory consulting firm founded in 2003. Her background consists of a distinguished pedigree in her field including serving as Deputy Commissioner and Senior Advisor at the U.S. Food and Drug Administration.
While at the FDA, Ms. Pendergast also served as Associate Chief Counsel for Enforcement and as Attorney, Office of the General Counsel, Dept. of Health and Human Services. She was responsible for FDA efforts to regulate emerging technologies such as cellular and tissue-based therapies, biotechnology, genetic testing, xeno-transplantation and acute-care research.
"We are honored to have added Ms. Pendergast to our team," states Lightlake Therapeutics CEO, Dr. Roger Crystal, "She has exceptional experience and expertise, that will help Lightlake navigate through the increasingly challenging regulatory landscape."
Chairman Dr Michael Sinclair added: "Mary's previous work with the FDA and in biotech will be invaluable for Lightlake, as we look to expand our portfolio into other areas, such as using opioid antagonists for the treatment of methadone dependency."
"I am very excited to be joining such an interesting venture. Lightlake's approach really differentiates itself and has the real potential to deliver where others have failed. Using single agents that are well known for their safety and effectiveness in related areas is very promising" commented Mary Pendergast.
Mary Pendergast received her LL.M., J.D., and B.A. degrees from Yale Law School, the University of Iowa College of Law, and Northwestern University, respectively.
About Lightlake Therapeutics
Lightlake Therapeutics is an early stage biopharmaceutical company aiming to build a solid platform of pharmacological treatments based on our expertise using opioid antagonists. Significant developments include the use of an opioid antagonist nasal spray to address binge-eating obesity. A Phase II trial of this product in Helsinki is due to be completed during 2011.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
CONTACT: Lightlake Therapeutics Inc Dr Roger Crystal, CEO roger.crystal@lightlake.fi Dr Michael Sinclair, Chairman michael.sinclair@lightlake.fi
